---

COMPLETE LEARNING NOTE: DRUG TREATMENT OF HEART FAILURE

From Absolute Beginner to MBBS Examination Mastery

---

---

SECTION 1: BIG PICTURE OVERVIEW

What problem does this drug class solve?

• The rooms further away from the pump get less water - they start to dry out (this is like your muscles getting weak and tired).
• Because the water is not moving forward, it starts to back up behind the pump - flooding the rooms on the input side (this is like fluid flooding your lungs and legs).

1. Unload the heart - reduce the work it has to do
2. Remove excess fluid - drain the backed-up flooding
3. Block the harmful compensatory systems - stop the body from destroying the heart with its own "rescue" attempts
4. Gently strengthen the heart - when truly needed
5. Prevent sudden death - from dangerous heart rhythms

• ACE inhibitors / ARBs / ARNIs (block the harmful hormonal cascade)
• Beta-blockers (protect the heart from adrenaline overdrive)
• Mineralocorticoid receptor antagonists (MRAs) like spironolactone
• SGLT2 inhibitors (the newest, game-changing class)

---

---

SECTION 2: BUILD THE FOUNDATION

2A: Normal Heart Physiology - What is normally happening?

• Right side: receives blue (deoxygenated) blood from the body, sends it to the lungs
• Left side: receives red (oxygenated) blood from the lungs, pumps it to the whole body

• Simple explanation: Of all the blood sitting in the left ventricle before a beat, what percentage actually gets pumped out?
• Normal value: 55-70%
• Analogy: If a bucket holds 100 mL and you squeeze 60 mL out each time, your ejection fraction is 60%.
• Medical importance: EF is THE most important number in heart failure classification.

• Simple explanation: How full is the heart before it contracts? How much stretch does the ventricle experience before beating?
• Analogy: Like how much you stretch a rubber band before letting it go. More stretch = more snap... but only up to a point.
• Medical term: The ventricular end-diastolic pressure/volume - governed by the Frank-Starling law.

• Simple explanation: The resistance the heart must push against when it pumps blood out.
• Analogy: Like the water pressure in your house pipes. If pipe pressure is very high, the pump has to work much harder to push water through.
• Medical term: Systemic vascular resistance (SVR) - primarily determined by arteriolar tone.

• Simple explanation: The intrinsic squeezing power of the heart muscle itself.
• Analogy: How strong is the pump motor? Separate from how full the bucket is (preload) or how much resistance the pipes have (afterload).
• Medical term: The force of myocardial contraction at any given preload and afterload.

• Simple explanation: The more the heart fills up (stretches), the harder it contracts - up to a point.
• Analogy: A rubber band snaps harder the more you stretch it - but eventually over-stretching makes it weak.
• Importance in HF: In early heart failure, the heart compensates by stretching more. Eventually this fails.

---

2B: What Goes Wrong in Heart Failure?

Step 1: The Trigger

• Coronary artery disease / heart attack (most common - dead muscle that cannot pump)
• Long-standing high blood pressure (forces the heart to pump against resistance for years)
• Leaky or tight heart valves
• Viral infection of heart muscle (myocarditis)
• Alcohol, drugs (cocaine, doxorubicin chemotherapy)
• Genetic cardiomyopathies

Step 2: The Immediate Consequence

Damaged heart muscle
       ↓
Reduced squeezing force (reduced contractility)
       ↓
Less blood pumped out per beat (reduced stroke volume)
       ↓
Reduced cardiac output (CO = Heart Rate × Stroke Volume)
       ↓
Tissues do not get enough oxygen

Step 3: The Body's Compensatory Responses (The Villain of the Story)

• Releases adrenaline (norepinephrine) and epinephrine
• Increases heart rate and contractility (short-term helpful)
• Constricts blood vessels to maintain blood pressure
• Long-term harm: Constant adrenaline bombardment damages the heart muscle, causes arrhythmias, and leads to cardiac remodeling (the heart enlarges and becomes dysfunctional)

• Reduced kidney blood flow triggers renin release
• Renin → Angiotensin I → Angiotensin II (via ACE enzyme)
• Angiotensin II causes:
  • Arteriolar constriction → raises blood pressure → INCREASES afterload on heart
  • Aldosterone release → sodium and water retention → INCREASES blood volume and preload
  • Direct toxic effects on heart muscle → fibrosis, remodeling
• Analogy: RAAS is like calling in a construction crew that claims to fix the leaking pipe but actually bulldozes the entire house.

• Causes water retention
• Worsens fluid overload

• The heart muscle hypertrophies (thickens) and dilates (stretches)
• Initially helps maintain output, but over time the dilated, stiff, thick heart functions WORSE
• This is called maladaptive remodeling

VICIOUS CYCLE OF HEART FAILURE:

Heart pumps less
     ↓
Body activates RAAS + SNS
     ↓
Fluid retained + vessels constrict
     ↓
Heart works harder against more resistance with more volume
     ↓
Heart gets damaged more
     ↓
Heart pumps even less
     ↓ (cycle repeats)

The Four Pillars Where Drugs Can Intervene

RAAS system → Block with ACE inhibitors, ARBs, ARNIs, MRAs
Sympathetic overdrive → Block with Beta-blockers
Fluid overload → Remove with Diuretics
Weak contractility → Boost with Digoxin, inotropes (cautiously)
Renal glucose handling → Target with SGLT2 inhibitors

---

2C: Types of Heart Failure

• EF less than 40%
• Also called "systolic heart failure"
• The heart cannot squeeze properly
• Most evidence-based treatments available here

• EF 50% or greater
• Also called "diastolic heart failure"
• The heart cannot relax properly - it is too stiff
• Harder to treat; fewer proven drugs

• EF 40-49%
• "The gray zone"

---

2D: Classification Systems

---

---

SECTION 3: DRUG CLASS FRAMEWORK

DRUG CLASS 1: DIURETICS

---

3.1A: What problem do diuretics solve?

---

3.1B: Loop Diuretics (The Heavy Artillery)

• The kidney filters blood through millions of tiny tubes (nephrons).
• In the thick ascending limb of the Loop of Henle, there is a special protein called the Na+/K+/2Cl- cotransporter (NKCC2).
• This transporter's job is to pull sodium, potassium, and chloride back into the blood, preventing urine from becoming too dilute.
• Loop diuretics BLOCK this transporter completely.

Loop diuretic blocks NKCC2
       ↓
Na+, K+, Cl- cannot be reabsorbed in the loop
       ↓
These ions stay in the tubule
       ↓
Water follows the osmotic gradient (stays in tubule)
       ↓
HUGE increase in urine output

---

3.1C: Thiazide Diuretics

• When a patient becomes resistant to loop diuretics, adding a thiazide (especially metolazone) to furosemide can dramatically enhance the diuretic effect.
• This works because thiazides block a different part of the nephron, preventing the compensatory sodium reabsorption that limits loop diuretic action.
• Warning: This combination can cause severe hypokalemia and electrolyte disturbances. Must be monitored closely.

• They RETAIN calcium (opposite of loop diuretics which waste calcium). Used in hypercalciuria.
• They WORSEN glucose tolerance (especially HCTZ). Avoid in diabetics if possible.
• They can cause hyperuricemia (gout).
• They are less effective when GFR < 30 mL/min (renal impairment) - except metolazone, which retains efficacy even in renal failure.

---

3.1D: Potassium-Sparing Diuretics

• Mild diuresis (Na excretion)
• Potassium RETENTION (hence "potassium-sparing")

---

DRUG CLASS 2: ACE INHIBITORS

---

3.2A: The RAAS Pathway - Full Detail

LIVER makes → Angiotensinogen (always circulating)
                    ↓
KIDNEY (juxtaglomerular cells) release → RENIN (when BP falls, Na falls, or SNS activated)
                    ↓
Renin cleaves Angiotensinogen → Angiotensin I (inactive)
                    ↓
ACE (Angiotensin Converting Enzyme) - found in lung endothelium
                    ↓
Angiotensin I → Angiotensin II (ACTIVE and HARMFUL in HF)
                    ↓
Angiotensin II acts on AT1 receptors:
  → Vasoconstriction (↑ afterload)
  → Aldosterone release (→ Na/water retention → ↑ preload)
  → ADH release (→ water retention)
  → Cardiac fibrosis and hypertrophy (direct toxic effect)
  → Sympathetic facilitation

• Less Angiotensin II is made (good)
• More bradykinin accumulates (good for vasodilation, bad for the cough side effect)

---

3.2B: ACE Inhibitors - Mechanism and Effects

1. Afterload reduction: Less Ang II → less vasoconstriction → arteries relax → heart pumps easier
2. Preload reduction: Less aldosterone → less Na/water retention → less blood volume → less overfilling
3. Reversal of remodeling: Less Ang II → less cardiac fibrosis, reduced hypertrophy over time
4. Mortality reduction: Multiple major trials (CONSENSUS, SOLVD) proved ACE inhibitors reduce death by 16-40%

• CONSENSUS trial (1987): Enalapril in severe HF (NYHA IV) → 40% reduction in mortality
• SOLVD trial (1991): Enalapril in NYHA II-III → 16% reduction in mortality

• Pregnancy
• Bilateral renal artery stenosis
• Hyperkalemia (K+ > 5.5 mmol/L)
• Angioedema with prior ACE inhibitor use
• Severe aortic stenosis (relative)

---

DRUG CLASS 3: ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)

• No cough (bradykinin is not affected - ACE still works)
• Can still cause angioedema (rare - but if severe angioedema occurs with ARB, do not re-challenge)
• Same benefits as ACE inhibitors for heart failure
• Used when patients cannot tolerate ACE inhibitors due to cough

---

DRUG CLASS 4: ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS (ARNIs)

1. Valsartan - blocks AT1 receptor (like an ARB)
2. Sacubitril - blocks neprilysin (an enzyme)

• Neprilysin is an enzyme that breaks down natriuretic peptides (ANP, BNP) and bradykinin.
• ANP (Atrial Natriuretic Peptide) and BNP (Brain Natriuretic Peptide) are released by the overstretched heart. They are the body's natural "pressure release valves" - they cause:
  • Vasodilation
  • Natriuresis (sodium excretion)
  • Reduced aldosterone secretion
  • Anti-fibrotic effects

Failing heart releases ANP and BNP
          ↓
These are normally broken down quickly by neprilysin
          ↓
Sacubitril blocks neprilysin
          ↓
ANP and BNP levels rise
          ↓
More vasodilation + more natriuresis + anti-fibrotic effects

• Sacubitril/valsartan vs. enalapril in 8,442 patients with HFrEF
• Sacubitril/valsartan reduced cardiovascular death and HF hospitalization by 20% more than enalapril
• This was a landmark trial - sacubitril/valsartan became the preferred agent over ACE inhibitors

• Hypotension (common - more vasodilatory than ACE inhibitors)
• Hyperkalemia
• Renal impairment
• Angioedema: Since sacubitril blocks bradykinin degradation (neprilysin degrades bradykinin), bradykinin accumulates → risk of angioedema. DO NOT use with ACE inhibitors (additive bradykinin accumulation = dangerous angioedema risk). Wait 36 hours after stopping ACE inhibitor before starting sacubitril/valsartan.

---

DRUG CLASS 5: BETA-BLOCKERS

---

3.5A: The Counterintuitive Story

• Heart failure = weak heart that cannot pump enough
• Beta-blockers reduce heart rate and contractility
• Logically: giving a drug that weakens an already-weak heart would be fatal

1. Destroys heart muscle cells (cardiotoxicity of catecholamines)
2. Causes dangerous arrhythmias (including ventricular fibrillation = sudden death)
3. Causes cardiac remodeling - heart dilates, becomes spherical, pumps worse over time
4. Depletes the heart's energy reserves

• Allow the heart to slow down and rest
• Prevent arrhythmias and sudden death
• Reverse cardiac remodeling over weeks to months (EF can actually IMPROVE)
• Reduce mortality dramatically

---

3.5B: Specific Beta-Blockers for Heart Failure

• Example: Carvedilol starts at 3.125 mg twice daily → target 25-50 mg twice daily
• NEVER start a beta-blocker in acutely decompensated (wet) heart failure
• Used only when patient is clinically stable (euvolemic, "dry")

---

DRUG CLASS 6: MINERALOCORTICOID RECEPTOR ANTAGONISTS (MRAs)

• Block aldosterone from binding to its intracellular receptor
• Prevent aldosterone from telling the kidney to reabsorb sodium and excrete potassium
• Result: Mild natriuresis, potassium RETENTION
• Additional benefit: Prevent aldosterone-induced cardiac and vascular fibrosis

• Spironolactone vs. placebo in severe HF (EF < 35%)
• 30% reduction in mortality
• Became standard of care

• Spironolactone: Cheap, non-selective, more side effects (gynecomastia, menstrual issues)
• Eplerenone: Expensive, selective aldosterone receptor, no hormonal side effects

---

DRUG CLASS 7: SGLT2 INHIBITORS

---

3.7A: Mechanism of SGLT2 Inhibitors

• SGLT2 (Sodium-Glucose Cotransporter 2) is located in the proximal convoluted tubule
• Its job: reabsorb nearly all filtered glucose AND sodium together
• SGLT2 inhibitors block this transporter → glucose AND sodium are excreted in urine

SGLT2 inhibitor blocks proximal tubule transporter
              ↓
Glucose AND sodium spill into urine
              ↓
Osmotic diuresis (glucose pulls water out)
              ↓
Natriuresis (sodium is lost)
              ↓
Reduced blood volume, reduced preload
              ↓
Reduced congestion in heart failure

1. Metabolic shift: Heart switches from glucose to ketone body metabolism - ketones are a more efficient fuel for the failing heart (the "thrifty substrate" hypothesis)
2. Anti-fibrotic effects: Reduce cardiac fibrosis and inflammation
3. Erythropoietin stimulation: May improve red cell production (helping oxygen delivery)
4. Renal protection: Reduce pressure on glomerular filtration, protecting kidneys
5. Sympathoinhibitory effects: Reduce sympathetic nervous activity

• DAPA-HF (2019): Dapagliflozin in HFrEF (EF < 40%) → 17% reduction in CV death + worsening HF
• EMPEROR-Reduced: Empagliflozin in HFrEF → similar benefits
• EMPEROR-Preserved and DELIVER trials: SGLT2 inhibitors also reduce HF hospitalizations in HFpEF - the FIRST drug class to show benefit in HFpEF

---

DRUG CLASS 8: CARDIAC GLYCOSIDES (DIGOXIN)

---

3.8A: History

---

3.8B: Mechanism of Digoxin - Step by Step

Digoxin inhibits Na+/K+-ATPase
         ↓
Na+ cannot be pumped out
         ↓
Intracellular Na+ concentration RISES
         ↓
This affects the Na+/Ca2+ exchanger (NCX)

↑ Intracellular Na+ → NCX works less effectively
         ↓
Ca2+ cannot exit the cell properly
         ↓
Intracellular Ca2+ concentration RISES
         ↓
This Ca2+ is stored in the sarcoplasmic reticulum (SR)
         ↓
On the next heartbeat, more Ca2+ is released from SR
         ↓
Stronger contraction (POSITIVE INOTROPIC EFFECT)

---

3.8C: Multiple Effects of Digoxin

• Via the Ca2+ mechanism above
• Useful in systolic heart failure

• Via vagal (parasympathetic) stimulation
• Digoxin increases vagal tone → slows SA node firing → slower heart rate
• Useful for rate control in atrial fibrillation with HF

• Again via vagal stimulation
• Slows AV conduction → controls ventricular rate in AF
• Can cause AV block in toxicity

---

3.8D: Pharmacokinetics of Digoxin

---

3.8E: Digoxin Toxicity - The Most Tested Topic in Cardiac Pharmacology

• Bradyarrhythmias: Sinus bradycardia, SA block, AV block (1st, 2nd, 3rd degree)
• Tachyarrhythmias: Paradoxically, digoxin can also cause tachycardia via "triggered activity" (delayed afterdepolarizations due to Ca2+ overload)
• The "classic" toxic rhythm: Paroxysmal Atrial Tachycardia with AV block - PATHOGNOMONIC of digoxin toxicity
• Also: Bidirectional ventricular tachycardia, PVCs (bigeminy/trigeminy)
• ECG: PR prolongation, ST depression ("scooping" or "reverse tick" sign), shortened QT, T wave changes

• Nausea, vomiting, anorexia (very early signs - often the FIRST warning)
• Diarrhea
• Neurological: confusion, headache, drowsiness, fatigue
• Visual disturbances: xanthopsia (yellow-green vision), blurred vision, halos around lights (one of the most famously tested symptoms)
• Gynaecomastia (long-term use - digoxin has weak estrogen-like effects)

1. Hypokalemia (most important!) - Potassium competes with digoxin at the Na+/K+-ATPase binding site. When K+ is low, more digoxin can bind → toxicity at normal serum levels. Diuretics cause hypokalemia → classic combination that causes toxicity.
2. Hypomagnesemia - Similar effect, worsens hypokalemia
3. Hypercalcemia - High Ca2+ acts like more digoxin (already elevated intracellular Ca2+)
4. Hypothyroidism - Reduced clearance of digoxin
5. Renal failure - Reduced excretion
6. Old age - Reduced renal clearance + decreased volume of distribution (less muscle mass)

• Amiodarone (major! - reduces renal and non-renal digoxin clearance; reduce digoxin dose by 50%)
• Quinidine (increases digoxin levels by displacing from tissue binding)
• Verapamil, Diltiazem (reduce digoxin clearance + additive AV block)
• Erythromycin/Tetracycline (prevent gut bacteria that convert digoxin to inactive metabolites → more digoxin absorbed)
• Spironolactone (interferes with digoxin assay, causes falsely elevated levels)

• Stop digoxin
• Correct hypokalemia (K+ infusion if low)
• Correct other electrolytes
• Cardiac monitoring
• Digoxin-specific antibody fragments (Digibind/DigiFab) - for severe toxicity. These antibodies bind digoxin molecules and neutralize them. Doses based on digoxin level and body weight.
• Atropine for bradycardia
• For ventricular arrhythmias: Lidocaine or phenytoin (NOT class IA antiarrhythmics like quinidine, which worsen toxicity)

---

3.8F: Current Role of Digoxin in Heart Failure

• Digoxin in HF with sinus rhythm
• Digoxin reduced HF hospitalizations by 27% but did NOT reduce mortality
• Digoxin did NOT cause more deaths (neither benefit nor harm on survival)
• At high serum levels (> 1.0 ng/mL), digoxin INCREASED mortality

1. HFrEF patients with atrial fibrillation - to control ventricular rate
2. HFrEF patients who remain symptomatic despite optimal quadruple therapy
3. NEVER first-line
4. Target serum level: 0.5-0.9 ng/mL (not the old therapeutic range of 0.5-2.0 ng/mL)

---

DRUG CLASS 9: VASODILATORS

Hydralazine + Isosorbide Dinitrate (ISDN)

1. Patients who cannot tolerate ACE inhibitors OR ARBs (e.g., renal failure, bilateral RAS, severe hyperkalemia)
2. African American patients with HF - they have a higher prevalence of reduced NO bioavailability, and the specific combination of hydralazine + ISDN has been shown to provide additional mortality benefit in this population (A-HeFT trial). Fixed-dose combination BiDil was approved specifically for Black patients.

• Hydralazine: Reflex tachycardia, drug-induced lupus (SLE-like syndrome), headache, fluid retention
• ISDN: Headache (very common, tolerance develops), hypotension, syncope

---

DRUG CLASS 10: IVABRADINE

• HFrEF patients with heart rate ≥ 70 bpm in sinus rhythm despite optimal beta-blocker therapy (or who cannot tolerate beta-blockers)
• Heart rate is an independent predictor of outcomes in HF - higher rates = worse outcomes

• Bradycardia (dose-limiting)
• Phosphenes/visual symptoms - flickering lights (if channel is in the retina too)
• Fetal harm (contraindicated in pregnancy)
• NOT effective in atrial fibrillation (there is no regular SA node activity to block)

---

DRUG CLASS 11: ACUTE DECOMPENSATED HEART FAILURE - SPECIAL DRUGS

• Nitrates (GTN infusion): Potent venodilators → rapid preload reduction → relieves pulmonary edema. Given sublingually or by infusion. Target: systolic BP > 90 mmHg.
• Sodium nitroprusside: Balanced arteriovenous dilator. Used in severe acute HF with hypertension. Cyanide toxicity with prolonged use (especially renal failure).
• Nesiritide (BNP): Recombinant BNP. Vasodilator + natriuretic. Not widely used due to lack of mortality benefit.

• Dobutamine: Beta-1 agonist → increases contractility and heart rate. Used short-term in acute decompensation. Does NOT improve survival long-term; can increase arrhythmias.
• Milrinone: Phosphodiesterase (PDE)-3 inhibitor → prevents breakdown of cAMP → increases cAMP in heart and blood vessels → positive inotropy + vasodilation (inodilator). Used in acute HF. More vasodilation than dobutamine.
• Dopamine: At low doses (2-5 mcg/kg/min): dopaminergic effects - renal vasodilation. At moderate doses (5-10 mcg/kg/min): beta-1 effects. At high doses (> 10 mcg/kg/min): alpha-1 effects - vasoconstriction.
• Levosimendan: Calcium sensitizer - makes cardiac muscle more sensitive to existing calcium without increasing calcium load. Does NOT increase oxygen demand. Also has PDE-3 inhibitor activity and opens K-ATP channels (vasodilation). Used in acute HF, especially post-cardiac surgery.

---

DRUG CLASS 12: IF CHANNEL BLOCKER IN HFpEF

• Control blood pressure (hypertension is the main cause)
• Control heart rate with beta-blockers
• Diuretics for congestion
• SGLT2 inhibitors (EMPEROR-Preserved and DELIVER showed benefit)
• Spironolactone (TOPCAT trial: benefit in Americas subgroup)
• ARNIs may benefit some patients

---

---

SECTION 4: TEACH USING ANALOGIES

The Complete Heart Failure Drug Analogy System

1. Close off smaller streets (vasoconstriction) to maintain pressure in main roads - this increases the pump's workload
2. Build more water storage tanks everywhere (fluid retention) - this overfills the system, flooding basements

• Remove the signal to constrict streets → lower pressure, easier for pump
• Remove the signal to fill more tanks → less flooding

• The pump has been running at maximum emergency speed for months, destroying its motors
• Beta-blockers let the pump slow down, rest, and actually REPAIR some damage over time

• Emergency pumps drain all the flooded basements immediately
• Quick symptom relief
• But they do not fix the damaged pump itself

• The pump station switches from expensive, inefficient gasoline to cleaner-burning natural gas
• Less waste, less pollution (inflammation/fibrosis), the whole system runs better

• Directly increases pump power
• But it is tricky - too much booster causes the pump to overheat and catch fire (toxicity)
• Used carefully, at low speeds

---

Mechanism Analogies for Exam Memory

---

---

SECTION 5: STEP-BY-STEP CLINICAL REASONING

Case 1: The Classic Heart Failure Patient

• This is heart failure. Post-infarct = likely HFrEF (ischemic cardiomyopathy).
• Confirm with echocardiogram - expected to show EF < 40%.
• BNP/NT-proBNP will be elevated.

• NYHA Class III (marked limitation - symptoms with mild activity)
• ACC/AHA Stage C

• He is SYMPTOMATIC (breathless, edematous) - he needs diuresis
• Start furosemide to relieve congestion: 40 mg orally once/twice daily

• Quadruple therapy:
  1. ACE inhibitor (or ARB if cough) OR sacubitril/valsartan if tolerated
  2. Beta-blocker - start ONLY once he is euvolemic (dry), not while still congested
  3. Spironolactone (EF < 35%)
  4. SGLT2 inhibitor (dapagliflozin or empagliflozin)

1. Diuretic first → relieve congestion
2. ACE inhibitor/ARNI next (can be started even with mild congestion)
3. Beta-blocker AFTER volume is controlled (start low, titrate up over weeks)
4. MRA + SGLT2i can be added once on stable ACE inhibitor/ARNI and beta-blocker

• Renal function and electrolytes 1-2 weeks after starting ACE inhibitor or MRA
• Weight daily (patient should weigh himself - any gain of 1-2 kg in 24-48h = fluid re-accumulation)
• BP monitoring
• Heart rate monitoring on beta-blocker

---

Case 2: Patient Develops Cough on ACE Inhibitor

• Is this from enalapril? Yes - dry cough in ~10-20% of patients on ACE inhibitors due to bradykinin accumulation
• Action: Switch to an ARB (e.g., valsartan, candesartan)
• ARBs provide same mortality benefit as ACE inhibitors without cough
• OR switch to sacubitril/valsartan (ARNI) for even better outcomes

---

Case 3: Atrial Fibrillation + Heart Failure

• Rapid ventricular rate in AF worsens HF (tachycardia-induced cardiomyopathy)
• Rate control needed
• First choice: Beta-blocker (also beneficial for HF)
• Alternative: Digoxin (useful for rate control in AF + HF; also provides mild inotropic benefit)
• If beta-blocker cannot control rate adequately: combine with digoxin
• Avoid verapamil/diltiazem (negative inotropes, worsen HF)
• Anticoagulation (CHA2DS2-VASc score) - likely needs warfarin or NOAC

---

Case 4: Digoxin Toxicity

• Digoxin toxicity - classic presentation (GI symptoms + xanthopsia + arrhythmia)
• Furosemide causes hypokalemia → potentiates digoxin toxicity
• Action:
  1. Stop digoxin immediately
  2. Check serum digoxin level and electrolytes (especially K+)
  3. Replace potassium if low
  4. ECG monitoring
  5. If severe arrhythmia or very high level: Digibind (digoxin-specific antibody)
  6. Never give Class IA antiarrhythmics (quinidine, procainamide) - they displace digoxin from tissue binding and worsen toxicity

---

---

SECTION 6: MEMORY TOOLS

6A: Mnemonics

Beta-blocker ACE inhibitor/ARB/ARNI MRA (Mineralocorticoid Receptor Antagonist) SGLT2 inhibitor

---

Ototoxicity Hypocalcemia (and hypokalemia, hyponatremia, hypomagnesemia - the hypos) Dehydration / volume depletion Alcalosis (metabolic alkalosis) Metabolic effects (hyperglycemia, hyperuricemia) Nephrotoxicity (pre-renal azotemia)

---

GI symptoms first (nausea, vomiting, anorexia) Arrhythmias (any arrhythmia, PAT with block is classic) Vision disturbances (xanthopsia, yellow-green, halos) Irregular pulse, bradycardia Neurological (confusion, fatigue)

---

Amiodarone (MOST IMPORTANT - 50% dose reduction needed) Verapamil Quinidine Quinolone antibiotics (macrolides also)

---

Carvedilol Bisoprolol Succinate of metoprolol (Metoprolol succinate CR/XL)

---

Bilateral renal artery stenosis Angioedema (previous) Renal failure (severe) / Raised K+ (hyperkalemia > 5.5) Kids (pregnancy - teratogenic)

---

6B: Drug Comparison Table

---

6C: Rapid Review Box - High Yield Facts

╔════════════════════════════════════════════════════════════════╗
║ HEART FAILURE RAPID REVIEW                                     ║
╠════════════════════════════════════════════════════════════════╣
║ 1. ONLY drugs that reduce MORTALITY in HFrEF:                  ║
║    ACE-I, ARBs, ARNIs, Beta-blockers, MRAs, SGLT2i            ║
║    (Diuretics and digoxin do NOT)                              ║
╠════════════════════════════════════════════════════════════════╣
║ 2. ONLY class with benefit in BOTH HFrEF + HFpEF:             ║
║    SGLT2 inhibitors                                            ║
╠════════════════════════════════════════════════════════════════╣
║ 3. First trial to show ANYTHING reduces HF mortality:          ║
║    V-HeFT I (1986) - Hydralazine + ISDN                       ║
╠════════════════════════════════════════════════════════════════╣
║ 4. Most powerful beta-blocker for HF (also has α1 block):     ║
║    Carvedilol                                                   ║
╠════════════════════════════════════════════════════════════════╣
║ 5. Digoxin reduces HF hospitalizations but NOT mortality       ║
╠════════════════════════════════════════════════════════════════╣
║ 6. ACE-I cough → switch to ARB or ARNI                        ║
╠════════════════════════════════════════════════════════════════╣
║ 7. CANNOT use ACE-I + ARNI together (angioedema risk)         ║
║    Wait 36 hours between stopping ACE-I and starting ARNI     ║
╠════════════════════════════════════════════════════════════════╣
║ 8. Most dangerous drug interaction in HF:                      ║
║    Digoxin + Amiodarone → reduce digoxin dose by 50%          ║
╠════════════════════════════════════════════════════════════════╣
║ 9. Hypokalemia + Digoxin = Toxicity (even at normal levels)   ║
╠════════════════════════════════════════════════════════════════╣
║ 10. Classic digoxin toxic rhythm:                              ║
║     Paroxysmal Atrial Tachycardia with AV block               ║
╚════════════════════════════════════════════════════════════════╝

---

---

SECTION 7: EXAMINER'S CORNER

7A: Most Tested Essay Questions

1. "Describe the pharmacological management of chronic heart failure with reduced ejection fraction."
2. "Write a note on the role of ACE inhibitors in heart failure."
3. "Describe the mechanism of action, adverse effects, and drug interactions of digoxin."
4. "How would you manage a patient with digoxin toxicity?"
5. "Discuss the role of RAAS blockade in heart failure."
6. "Compare and contrast ACE inhibitors and ARBs in heart failure."
7. "Write a note on SGLT2 inhibitors in heart failure."
8. "Discuss the mechanism by which beta-blockers reduce mortality in heart failure despite being negative inotropes."

---

7B: Most Likely Short Notes

1. Digoxin toxicity - signs, management
2. Spironolactone in heart failure
3. Sacubitril/valsartan (ARNI)
4. SGLT2 inhibitors in heart failure
5. Carvedilol
6. Differences between loop and thiazide diuretics
7. Levosimendan
8. Sequential nephron blockade

---

7C: Common Viva Questions and Model Answers

---

7D: Most Likely MCQs

1. Q: A patient on digoxin and furosemide develops nausea and visual changes. What is the most likely cause? A: Digoxin toxicity precipitated by furosemide-induced hypokalemia
2. Q: Which of the following is the antidote for life-threatening digoxin toxicity? A: Digoxin-specific antibody fragments (Digibind/DigiFab)
3. Q: A patient develops dry cough on enalapril. What is the most appropriate next step? A: Switch to an ARB (e.g., valsartan) or ARNI (sacubitril/valsartan)
4. Q: Which beta-blocker also has alpha-1 blocking activity? A: Carvedilol
5. Q: The PARADIGM-HF trial demonstrated superiority of which drug over enalapril? A: Sacubitril/valsartan (ARNI)
6. Q: Which diuretic can be used for diuresis even when GFR < 30 mL/min? A: Metolazone (thiazide) or loop diuretics (furosemide)
7. Q: Which drug class is the ONLY one proven effective in both HFrEF and HFpEF? A: SGLT2 inhibitors
8. Q: A patient with HF develops PAT (paroxysmal atrial tachycardia) with AV block on ECG. What is the diagnosis? A: Digoxin toxicity
9. Q: Amiodarone co-administration with digoxin requires what dose adjustment? A: Reduce digoxin dose by 50% (amiodarone doubles digoxin levels)
10. Q: Levosimendan exerts its inotropic effect by: A: Sensitizing cardiac muscle to calcium (calcium sensitizer mechanism)

---

7E: Common Traps Students Fall Into

---

---

SECTION 9: HIGH-YIELD REVISION SHEET

╔═══════════════════════════════════════════════════════════════════════╗
║          HEART FAILURE PHARMACOLOGY - MASTER REVISION SHEET           ║
╠═══════════════════════════════════════════════════════════════════════╣
║ DEFINITIONS                                                            ║
║ HFrEF = EF < 40% (systolic failure, pump can't squeeze)               ║
║ HFpEF = EF ≥ 50% (diastolic failure, heart can't relax/fill)          ║
║ NYHA I-IV = functional classification; ACC/AHA A-D = structural stages║
╠═══════════════════════════════════════════════════════════════════════╣
║ QUADRUPLE THERAPY FOR HFrEF (BAMS) - ALL FOUR REDUCE MORTALITY       ║
║ B = Beta-blocker (carvedilol, metoprolol succinate, bisoprolol)       ║
║ A = ACE-I / ARB / ARNI (sacubitril/valsartan preferred over ACE-I)   ║
║ M = MRA (spironolactone or eplerenone; EF < 35%)                      ║
║ S = SGLT2 inhibitor (dapagliflozin or empagliflozin)                  ║
╠═══════════════════════════════════════════════════════════════════════╣
║ DIURETICS (symptom relief, NOT mortality benefit)                     ║
║ Loop = furosemide (NKCC2 blocker); used first for congestion          ║
║ Spironolactone = K+-sparing + mortality benefit via MRA action        ║
║ Metolazone = thiazide; add to furosemide for diuretic resistance      ║
╠═══════════════════════════════════════════════════════════════════════╣
║ DIGOXIN                                                                ║
║ MOA: Inhibits Na+/K+-ATPase → ↑Na+ → ↓NCX → ↑Ca2+ → stronger beat  ║
║ Also: ↑vagal tone → bradycardia, ↓AV conduction                       ║
║ Use: Rate control in AF + HF; symptomatic HFrEF only                  ║
║ Target level: 0.5-0.9 ng/mL (NOT > 1.0 ng/mL)                        ║
║ Toxicity precipitants: Hypokalemia (most important!), renal failure,  ║
║                         hypomagnesemia, hypercalcemia, amiodarone      ║
║ Classic toxic rhythm: PAT with AV block                                ║
║ Classic toxic symptom: Xanthopsia (yellow-green vision)               ║
║ Antidote: Digibind (digoxin-specific antibody fragments)              ║
╠═══════════════════════════════════════════════════════════════════════╣
║ KEY DRUG INTERACTIONS                                                  ║
║ Digoxin + Amiodarone → ↑↑ Digoxin levels (reduce dose by 50%)        ║
║ ACE-I + ARNI → severe angioedema (ABSOLUTELY CONTRAINDICATED)         ║
║ Loop diuretic + MRA → watch for profound hypokalemia OR hyperkalemia ║
║ Furosemide + aminoglycosides → ↑ ototoxicity risk                     ║
╠═══════════════════════════════════════════════════════════════════════╣
║ KEY CONTRAINDICATIONS                                                  ║
║ ACE-I: Pregnancy, bilateral RAS, angioedema, hyperkalemia             ║
║ Beta-blocker: Acute decompensated HF, asthma (non-selective),        ║
║               cardiogenic shock, high-degree AV block                 ║
║ ARNI + ACE-I: Together - NEVER; 36h washout needed                   ║
║ Spironolactone: K+ > 5.0, GFR < 30, pregnancy                        ║
║ Ivabradine: AF (no SA node to target), HR < 70                        ║
╠═══════════════════════════════════════════════════════════════════════╣
║ LANDMARK TRIALS                                                        ║
║ V-HeFT I (1986): First HF mortality trial - Hydralazine + ISDN       ║
║ CONSENSUS (1987): Enalapril - 40% mortality ↓ in NYHA IV             ║
║ SOLVD (1991): Enalapril - 16% mortality ↓ in NYHA II-III             ║
║ RALES (1999): Spironolactone - 30% mortality ↓                        ║
║ MERIT-HF (1999): Metoprolol CR/XL - 34% mortality ↓                  ║
║ DIG (1997): Digoxin - no mortality benefit; 27% ↓ hospitalizations   ║
║ PARADIGM-HF (2014): Sacubitril/valsartan - 20% ↓ vs enalapril        ║
║ DAPA-HF (2019): Dapagliflozin - 17% ↓ in HFrEF                       ║
╠═══════════════════════════════════════════════════════════════════════╣
║ SPECIAL CLINICAL PEARLS                                                ║
║ • Small rise in creatinine on ACE-I = acceptable (up to 30%)         ║
║ • Large rise in creatinine on ACE-I = think bilateral renal stenosis ║
║ • Ethacrynic acid = only non-sulfonamide loop diuretic                ║
║ • Carvedilol = only β-blocker with α1 blockade                        ║
║ • Ivabradine = only approved If channel blocker                        ║
║ • Levosimendan = only calcium sensitizer available                    ║
╚═══════════════════════════════════════════════════════════════════════╝

---

---

SECTION 10: SELF-ASSESSMENT

10 Short-Answer Questions with Explanations

---

---

---

---

---

1. Valsartan: Blocks AT1 receptor → reduces the harmful effects of Angiotensin II
2. Sacubitril: Inhibits neprilysin, the enzyme that degrades natriuretic peptides (ANP, BNP, CNP)

---

---

---

---

1. Natriuresis and osmotic diuresis: They reduce sodium AND water reabsorption in the proximal tubule → reduces blood volume → reduces preload and congestion
2. Metabolic substrate shift: The failing heart preferentially switches to ketone body metabolism (SGLT2 inhibitors slightly elevate circulating ketones). Ketone oxidation is more efficient than glucose metabolism in the energy-deficient heart
3. Anti-fibrotic effects: Reduce TGF-β and reduce myocardial and renal fibrosis
4. Cardiorenal protection: By reducing intraglomerular pressure, they protect kidneys, and improved renal function benefits the heart
5. Sympathoinhibitory effects: May reduce sympathetic nervous system activation

---

1. Severe hypovolemia / dehydration: The patient is already volume-depleted. Adding a diuretic will cause circulatory collapse, pre-renal acute kidney injury, and potentially ischemia of vital organs. Loop diuretics reduce preload further in an already underfilled state.
2. Anuria: If the kidneys are not producing urine at all, diuretics cannot work. They depend on renal tubular function to exert their effect. In true anuria from end-stage renal failure, diuretics are futile. Additionally, pushing furosemide in this setting carries nephrotoxicity risk.
3. Hypersensitivity / sulfonamide allergy (for furosemide, bumetanide, torsemide): These drugs contain a sulfonamide group. In true sulfonamide allergy, use ethacrynic acid (the only non-sulfonamide loop diuretic, but more ototoxic).
4. Hepatic coma associated with hyponatremia: Aggressively diuresing a patient with liver failure and hepatic encephalopathy can precipitate electrolyte crises (particularly severe hyponatremia from free water retention). In cirrhosis with hepatic encephalopathy, the metabolic derangements from diuresis can worsen the encephalopathy. Careful, gradual diuresis under monitoring is needed, not aggressive loop diuretic treatment.

---

---